Much Ado About Nothing Much With Atara's MS Hopeful
Interim Analysis On ATA188 Reveals Little
Investors and most analysts were not impressed with a much-anticipated Phase II update on Atara’s allogeneic T-cell immunotherapy which could be transformational as a treatment for multiple sclerosis, but some observers believe the slump in the firm’s stock was not merited.
You may also be interested in...
After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
Faced with a scarily short cash runway and an ongoing expensive mid-stage study of an allogeneic cell therapy for the treatment of delayed-union bone fractures, Bone Therapeutics has found a saviour in France's Medsenic.
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.